Capital Advisors Ltd’s FibroBiologics FBLG Stock Holding History

Capital Advisors Ltd’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1	Closed	–	–	1612
2024 Q3	$0	Buy	+1	New	+$66	﹤0.01%	1637

Other funds holding FBLG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CFP

Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OAS

Optivise Advisory Services Franklin, Tennessee $197M AUM 26.07% 1-Year Est. Return

RCM

Requisite Capital Management Dallas, Texas $537M AUM 12.29% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital Advisors Ltd's FBLG Position: Q4 2024 in Review

Capital Advisors Ltd sold out of FibroBiologics (FBLG) in Q4 2024, closing a stake of 1 share.

Capital Advisors Ltd first reported a position in FBLG in Q3 2024 and held it in 1 quarter. The position peaked at $0 in Q3 2024. 63 funds tracked by Wall St. Rank hold FBLG as of Q4 2024.

Capital Advisors Ltd reported no remaining FibroBiologics position as of Q4 2024 after selling out during the quarter.
Capital Advisors Ltd sold 1 FibroBiologics share in Q4 2024.
Capital Advisors Ltd first reported a position in FibroBiologics in Q3 2024 and held it in 1 quarter.
Capital Advisors Ltd's FibroBiologics position peaked at $0 in Q3 2024.
63 funds tracked by Wall St. Rank held FibroBiologics as of Q4 2024.

Based on Capital Advisors Ltd's 13F filing for Q4 2024, filed 4 Feb 2025.